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SUMMARY – Th e aim of this study was to investigate the role of the QuantiFERON-TB Gold 
In-Tube test (QFT-GIT) in detecting latent tuberculosis in immunocompromised patients before 
introducing tumor necrosis factor (TNF-α) antagonists. Th e study included 300 subjects of similar 
age. Th e study group comprised of 150 QuantiFERON (QFT) positive subjects with rheumatoid 
arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis and psoriatic arthritis, while control 
group comprised of 150 QFT negative respondents with the same diseases. Exhaustive medical his-
tory was documented for all patients. Screening tests were performed including QFT-GIT, tuberculin 
skin test (TST), chest radiography and detection of Mycobacterium tuberculosis in sputum culture 2 
times. A positive QFT-GIT test result, regardless of TST result, was considered as an indication for 
latent tuberculosis infection (LTBI) treatment. Results of this study showed good correlation between 
the conclusive results of QFT-GIT and TST. All study group patients had normal clinical fi ndings, 
normal radiologic fi ndings and negative results of sputum microbiological analysis during the course 
of prophylaxis and after its completion and during the course of biological therapy. Conversion of 
positive QFT-GIT test to negative was observed in 4% of study group patients, while QFT negative 
respondents remained negative. Th ere was a statistically signifi cant positive correlation between QFT-
GIT, TST results and patient age, smoking habit and contact with tuberculosis. Study results showed 
that along with good clinical evaluation and detailed medical history, it is important to conduct testing 
in order to avoid disease progression or unnecessary isoniazid prophylaxis.
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Introduction
Since tuberculosis is associated with tumor necrosis 
factor alpha (TNF-α) blockade, the widespread use of 
TNF-α antagonists for infl ammatory diseases has led 
to an increased rate of active tuberculosis cases1. Ar-
thritis patients are at a higher risk of infection because 
of the disease and immunosuppressive therapies, in-
cluding prednisolone, disease-modifying anti-rheu-
matic drugs (DMARDs) and TNF-α antagonists2,3. 
Most biologics appear to be similar in their propensity 
to promote serious infection4.
Latent tuberculosis infection (LTBI) is the pres-
ence of Mycobacterium tuberculosis (TB) without any 
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symptoms of active disease. Detection of LTBI is im-
portant in clinical practice due to its associated risk of 
progression to active disease, especially in immuno-
compromised population1.
Th ere are no clinical symptoms and signs in LTBI 
and no gold standard laboratory test is available. Until 
recently, the tuberculin skin test (TST) was the only 
test available for diagnosing LTBI. Th e sensitivity and 
specifi city of TST are considered generally low, under 
100%, with the occurrence of false-negative results due 
to depressed immunity and false-positive results due 
to previous Bacillus Calmette-Guérin (BCG) immu-
nization and cross-reactivity with opportunistic myco-
bacteria. It also has limitations including a signifi cant 
false-positive rate and poor sensitivity in immuno-
compromised individuals2,5,6. Another available test for 
detection of LTBI is QuantiFERON-TB Gold In-
Tube (QFT-GIT) test, which has been demonstrated 
to have comparable sensitivity to TST for LTBI, but 
its strength appears to be in its superior specifi city, par-
ticularly in BCG-vaccinated population and its better 
correlation with the known TB risk factors.
It seems to off er better possibility of improved de-
tection of LTBI, however, data on its performance in 
arthritis patents are limited5-13.
Th is article reviews the role of the QFT-GIT test 
in the diagnosis of latent tuberculosis infection in ar-
thritis patients prior and during TNF-α antagonist 
therapy.
Patients and Methods
During one-year study period, 300 patients under-
went treatment with TNF-α antagonists. Th e study 
group comprised of 150 QuantiFERON (QFT) posi-
tive patients (mean age, 51.8; 82 women and 68 men) 
suff ering from rheumatoid arthritis, Crohn’s disease, 
ulcerative colitis, ankylosing spondylitis and psoriatic 
arthritis, while control group comprised of 150 QFT 
negative respondents (mean age, 45.98; 75 women and 
75 men) with the same diseases. Exhaustive medical 
history was documented for all subjects. A pre-struc-
tured questionnaire on comorbidity, drug intake, fam-
ily history of tuberculosis, epidemiological history (tu-
berculosis contact, country of birth), occupation, BCG 
immunization, smoking habits and alcohol consump-
tion was fi lled out for each subject.
During the fi rst clinical examination, both QFT-
GIT (QFT-GIT test; Cellestis Ltd., Carnegie, Victo-
ria, Australia) and TST were performed. Th e QFT-
GIT test was performed according to the manufac-
turer’s instructions and positive test result was defi ned 
as ≥0.35 IU/mL, while the TST was performed using 
the Mantoux method with 2 tuberculin units (TU) of 
purifi ed protein derivative RT23 (Statens Serum In-
stitute, Copenhagen, Denmark) on the volar side of 
the forearm. Induration size was measured after 48-72 
hours, while 10-mm induration was positive cut-off  
value for the TST.
To rule out active disease in all subjects, detailed 
clinical evaluation included physical examination, 
chest radiographs and microbiological analysis for 
Mycobacterium tuberculosis (sputum culture 2 times).
In subjects with positive QFT-GIT test regardless 
of TST result and normal chest radiographs and nega-
tive microbiological examination, 6-month prophy-
laxis with isoniazid was introduced, whereas TNF-α 
antagonist treatment was initiated 6 weeks after iso-
niazid introduction. In QFT negative subjects, TNF-α 
antagonist treatment was introduced immediately. 
TST was administered 3 days prior to QFT-GIT to 
rule out inaccurate results, since TST appeared to af-
fect QFT-GIT responses, especially in QFT-GIT 
negative subjects but only after 3 days and may appar-
ently persist for several months, although with scarce 
evidence14.
In all subjects, second clinical evaluation was per-
formed six months after the fi rst visit and included 
physical examination and chest radiographs, while 
third clinical evaluation was performed after one year 
and included physical examination, chest radiographs, 
microbiological analysis for Mycobacterium tuberculosis 
(sputum culture 2 times) and QFT-GIT test.
Ethics
Prior to signing a written consent, each patient was 
thoroughly informed about the purpose of the study. 
Th e study was approved by the Ethics Committee, 
School of Medicine, University of Zagreb.
Statistics
Statistical analysis was performed using the STA-
TISTICA 12.0 software package (StatSoft, Inc., 
USA). Basic statistical parameters for continuous vari-
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ables and frequency tables for categorical variables 
were calculated separately for both control and study 
groups. Th e c2-test was used to identify percentage dif-
ference between the groups. Mann-Whitney U test 
was used to assess the possible statistically signifi cant 
diff erences between the two groups, whereas Kruskal-
Wallis ANOVA was employed for more than two 
groups. Linear regression analysis was used to deter-
mine the possible correlation between QFT-GIT and 
TST results.
To defi ne the infl uence of selected predictor vari-
ables (age, sex, immune diseases, other diseases, smok-
ing, alcohol consumption, and contact with tuberculo-
sis) on the dependent variable (QFT-GIT, TST), 
multiple regression analysis and general regression 
model (GRM) were used. Pareto distribution diagram 
was used to show GRM results in T value. Statistical 
signifi cance at 0.05 level was used in all methods.
Results
Th e incidence of immune system diseases was 
equally distributed in subjects with positive QFT-GIT 
and TST. Rheumatoid arthritis was the most prevalent 
disease in both QFT and TST positive subjects 
(38.67% QFT positive and 40% TST positive), fol-
lowed by Crohn’s disease (24% QFT positive and 
23.33% TST positive), whereas other diseases were 
less frequent. Adalimumab was the most prescribed 
biological therapy (Table 1).
Among QFT positive subjects, 80.67% were also 
TST positive (Table 2), whereas 2.67% of QFT ne-
gative respondents had positive TST results. Linear 
regression analysis revealed a very good correlation 
 between QFT-GIT and TST results (R=0.74; p=
0.000000).
Th irty percent of study subjects and 10% of control 
subjects had a history of tuberculosis contact. Th e 
 percentage of patients with tuberculosis contact was 
signifi cantly lower in the control group (χ2=14.2; p=
0.0002).
Tuberculosis contact as a risk factor had a statisti-
cally signifi cant eff ect on QFT-GIT and TST results. 
Seventy-fi ve percent of respondents with a history of 
tuberculosis contact had positive QFT-GIT test re-
sults, while 80% had positive TST results. In the QFT 
positive group, 25 of 45 subjects with a history of tu-
berculosis contact had moderate reaction (fi rm bump 
Table 1. Biological therapy distribution in study 
(QFT positive) and control (QFT negative) groups
Biological therapy
Study group Control group
n % n %
Tocilizumab 5 3.33 7 4.67
Etanercept 45 30.00 47 31.33
Adalimumab 72 48.00 72 48.00
Golimumab 3 2.00 13 8.67
Infl iximab 23 15.33 8 5.33
Rituximab 2 1.33 3 2.00
QFT = QuantiFERON test
Table 2. Distribution of respondents considering 
TST results in study (QFT positive) and control 
(QFT negative) groups
TST test
Study group Control group
n % n %
Negative reaction 
(no fi rm bump 
at the test site)
29 19.33 146 97.33*
Moderate positive 
reaction (fi rm bump 
of 5 mm (0.2 in.) 
in size)
99 66.00 4 2.67*
Strong positive 
reaction
(fi rm bump of 10 mm 
(0.4 in.) in size)
22 14.67
0 0
TST = tuberculin skin test; QFT = QuantiFERON test; *statisti-
cally signifi cant diff erence between control and study groups con-
sidering TST results
of 5 mm (0.2 in.) in size), 19 subjects had strong reac-
tion (fi rm bump of 10 mm (0.4 in.) in size), and only 
one subject had no reaction during TST testing (no 
fi rm bump at the test site). Th e Kruskal-Wallis ANO-
VA test and Mann-Whitney U test results (Table 3) 
showed that the variables of age, smoking and tuber-
culosis contact had a statistically signifi cant impact on 
the QFT-GIT and TST results.
Regression analysis confi rmed a statistically sig-
nifi cant correlation between the selected predictor 
variables and QFT-GIT test results (R=0.55; p=
0.000002). Beta coeffi  cient values indicated the vari-
ables of tuberculosis contact (β=0.23; p=0.000152), 
subject age (β=0.21; p=0.001415) and smoking habit 
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(β=0.11; p=0.048893) to have by far greatest statisti-
cally signifi cant eff ect on QFT-GIT test results.
A statistically signifi cant correlation was also con-
fi rmed between the same predictor variables and TST 
results (R=0.71; p=0.000000). Tuberculosis contact 
(β=0.47; p=0.000000), subject age (β=0.15; p=0.016634) 
and smoking habits had the greatest, statistically sig-
nifi cant contribution to the overall correlation.
After one-year study period, 4% of subjects from the 
study group experienced conversion of QFT-GIT test 
from positive to negative, whereas all QFT negative 
subjects remained negative. According to the regression 
model results, none of the selected predictor variables 
had a statistically signifi cant impact on QFT-GIT test 
negativization after chemoprophylaxis.
After six-month and one-year period, all subjects 
had normal clinical, radiological and microbiological 
fi ndings of sputum, regardless of chemoprophylaxis 
and biological therapy.
Discussion
It is important to establish accurate diagnosis of 
latent tuberculosis in patients suff ering from infl am-
matory autoimmune diseases during TNF-α antago-
nist therapy due to the high risk of its progression to 
an active form and an increased risk of developing 
some of the more complicated forms of tuberculo-
sis1,3,5.
Based on the QFT-GIT test results, subjects in 
this study were divided into two groups; 80.67% of the 
QFT positive subjects had positive TST results, indi-
cating good correlation between QFT-GIT and TST 
results.
In the majority of other studies, greater diff erence 
between QFT-GIT and TST results has been docu-
mented2,5,15-17. Such a diff erence, which favors QFT-
GIT test performance, appears to be due to the false-
positive TST results because of previous BCG immu-
nization and due to false-negative TST results in im-
munocompromised patients2,5,15-17.
In this study, the prevalence of the history of tuber-
culosis contact was signifi cantly higher in the study 
group as compared with the control group (30%:10%). 
In the control, QFT negative group, only 15 subjects 
had tuberculosis contact. When TST was performed, 
only two subjects had moderate reaction, whereas 13 
subjects had no reaction. Positive TST results in these 
two QFT negative patients who had a history of tu-
berculosis contact and in another two subjects with no 
history of tuberculosis contact but having TST posi-
tive and QFT-GIT negative results can be interpreted 
as a false-positive TST result, which can occur due to 
previous BCG immunization and cross-reactivity with 
non tuberculosis mycobacteria, but not to the extent 
reported from other studies where this diff erence was 
much greater2,5,6,15-17.
Hsia et al.5 documented that positive TST result was 
3-fold higher in BCG-vaccinated than in unvaccinated 
patients, while the proportion of patients with positive 
QFT-GIT test results was only 1.5-fold higher in 
BCG-vaccinated compared with unvaccinated patients. 
In this study, all patients were BCG-vaccinated. It is 
important to mention that one-fi fth of QFT positive 
patients in this group were TST negative. In this study, 
greater sensitivity of QFT-GIT test as compared to 
TST, although not statistically signifi cant, was consis-
tent with other so far documented studies, especially 
when it comes to immunocompromised patients1,2,5. 
Some of these studies have reported similar QFT-GIT 
test results between immunocompromised and healthy 
subjects, whereas positive TST results were signifi cantly 
lower in immunocompromised patients when com-
pared with healthy subjects5,10.
Although a large proportion of patients in our 
study were receiving methotrexate and other DMARDs, 
at the beginning of the study lower corticosteroid 
 doses were used (10 mg/day) and none of the patients 
received TNF-α antagonist therapy, so generally 
speaking, no patient had severe comorbid infection. 
Table 3. Kruskal-Wallis ANOVA test 
and Mann-Whitney U test results shown as p values 
for QFT-GIT and TST, for selected dependent variables
Variable QFT-GIT test TST test
Age 0.0001* 0.0163*
Sex 0.4192 0.9292
Immune disease 0.7650 0.8192
Other diseases 0.0752 0.1728
Smoking 0.0070* 0.0010*
Alcohol consumption 0.0619 0.0540
Tuberculosis contact 0.0000* 0.0000*
QFT-GIT = QuantiFERON-TB Gold In-Tube test; TST = tuber-
culin skin test; *statistically signifi cant diff erence (p<0.05)
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Such immunosuppression did not appear to have a 
substantial eff ect on TST and QFT-GIT test results.
After six weeks of tuberculosis prophylaxis schemes 
used in this study (6 months of isoniazid), TNF-α an-
tagonist therapy was introduced in QFT positive re-
spondents. Among TNF-α antagonists, adalimumab 
was most frequently prescribed (48% of subjects), fol-
lowed by etanercept (30% of subjects).
On second clinical evaluation conducted six 
months after the fi rst visit and during third clinical 
evaluation after one-year period, all physical examina-
tions, chest radiographs and microbiological analysis 
for Mycobacterium tuberculosis (sputum culture 2 times) 
revealed normal fi ndings in all patients included in the 
study. After one-year period, QFT-GIT test was per-
formed again in all patients. Conversion to negative 
result was recorded in 4% of QFT positive subjects, 
while all QFT negative patients remained negative.
In the United Kingdom (UK), a risk-based strategy 
such as the BTS UK pre-anti-TNF-α guideline is rec-
ommended18. Th is emphasizes clinical assessment, and 
balances the annual risk of developing active tubercu-
losis (using country of birth and age) against the 
chance of hepatotoxicity during treatment for LTBI. 
Th is guideline is in line with the low expected back-
ground prevalence of Mycobacterium tuberculosis in UK 
population, therefore QFT-GIT test results are more 
likely to be false than genuine true-positive in that 
kind of population19.
Although TNF-α antagonist candidates are ex-
pected to be at no greater risk of exposure to Mycobac-
terium tuberculosis than the background population in 
general, a higher risk of tuberculosis was previously 
observed among patients with rheumatoid arthritis 
treated with prednisolone and DMARDs3. In this 
study, rheumatoid arthritis was one of the most fre-
quently present immune diseases with two-times 
higher incidence in women than in men. Th erefore, 
performing QFT-GIT test in that kind of population 
remains fully justifi ed.
Since the BTS guideline was published, the Na-
tional Institute for Health and Clinical Excellence has 
issued a guideline discussing non-HIV associated 
cause of immunosuppression, although not specifi cally 
mentioning pre-TNF-α antagonist assessment. Th is 
recommends that screening should include QFT-GIT 
and/or TST in immunocompromised subjects20.
Greveson et al.1 found QFT-GIT testing to be 
more favorable than TST in low incidence population 
where most of the subjects experienced previous BCG 
immunization, thus avoiding false-positive TST re-
sults. Th is is consistent with our results, as all QFT 
negative but TST positive patients remained negative 
at the end of the study and, what is most important, 
did not experience tuberculosis although were admin-
istered anti TNF-α therapy without previous prophy-
laxis.
In our study, older age, history of contact with tu-
berculosis and smoking signifi cantly infl uenced the 
QFT-GIT and TST results, pointing to the impor-
tance of good clinical examination and detailed medi-
cal history, which is in line with the UK pre-TNF-α 
antagonist guideline18.
In our analysis, QFT-GIT test showed somewhat 
greater sensitivity and specifi city when compared with 
TST, however, without statistical signifi cance, showing 
that there is no gold standard for LTBI diagnosis and 
that every case should be analyzed thoroughly. Th is in-
cludes complete medical evaluation and detailed med-
ical history. However, unlike TST, QFT-GIT does not 
require re-visit and its interpretation is less vulnerable 
to reader error, making this test more favorable. Since 
the number of patients suff ering from infl ammatory 
autoimmune diseases in need of TNF-α antagonist is 
increasing in Croatia, a large cost-eff ectiveness evalua-
tion should be performed. Nevertheless, patients 
should be informed regarding LTBI assessment, its 
implications and possible on-going risks.
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Sažetak
PRIMJENA QuantiFERON-TB Gold In-Tube TESTA U DIJAGNOZI LATENTNE TUBERKULOZE 
ZA VRIJEME PRIMJENE ANTAGONISTA TUMORSKE NEKROZE 
KOD OSOBA KOJE BOLUJU OD ARTRITISA
D. Baričević, S. Popović Grle, J. Morović Vergles, S. Čuković Čavka, M. Jakopović, G. Redžepi, Z. Boras, 
M. Baričević i M. Samaržija
Cilj ovoga istraživanja bio je ispitati ulogu testa QuantiFERON-TB Gold In-Tube (QFT-GIT) u otkrivanju latentne 
tuberkuloze u imunokompromitiranih bolesnika prije terapije antagonistima tumor nekrotizirajućeg čimbenika alfa (TNF-α). 
U istraživanju je sudjelovalo 300 ispitanika slične životne dobi. Ispitnu skupinu činilo je 150 ispitanika pozitivnih na testu 
QuantiFERON (QFT) koji su bolovali od reumatoidnog artritisa, Crohnove bolesti, ulceroznog kolitisa, ankilozantnog 
spondilitsa te psorijatičnog artritisa, dok je kontrolnu skupinu činilo 150 ispitanika negativnih na testu QFT koji su bolo vali 
od istih bolesti. Od svih ispitanika uzeta je detaljna medicinska anamneza. Od dijagnostičkih testova učinjen je test 
QFT-GIT, kožni tuberkulinski test (TST), rtg pluća te sputum na Mycobacterium tuberculosis 2 puta. Pozitivan test 
QFT-GIT bez obzira na rezultate kožnog tuberkulinskog testa smatrao se indikacijom za liječenje latentne tuberkuloze. 
Rezultati ovoga istraživanja pokazali su dobru korelaciju između testova QFT-GIT i TST. Svi ispitanici ispitne skupine su 
za vrijeme provođenja profi lakse i nakon njezina završetka te za vrijeme provođenja biološke terapije imali uredan klinički 
nalaz, uredan radiološki nalaz te negativan nalaz mikrobiološke analize sputuma. U ispitnoj skupini je 4% ispitanika imalo 
konverziju pozitivnog testa QFT-GIT u negativan, dok su svi ispitanici negativni na testu QFT ostali negativni. Potvrđena 
je statistički značajna pozitivna korelacija između rezultata testova QFT-GIT i TST te životne dobi ispitanika, pušenja i 
kontakta s tuberkulozom. Rezultati pokazuju da je uz dobar klinički pregled i detaljnu anamnezu važno provesti testiranja 
kako bi se spriječila progresija bolesti odnosno profi laksa izonijazidom.
Ključne riječi: Tuberkulinski test; Latentna tuberkuloza – dijagnostika; Artritis; Tumorski nekrotički faktori – antagonisti i 
inhibitori; Biološka terapija; Hrvatska
